Rostafuroxin

Last updated
Rostafuroxin
Rostafuroxin.svg
Names
IUPAC name
21,23-Epoxy-24-nor-5β-chola-20,22-diene-3β,14β,17-triol
Systematic IUPAC name
(1S,3aS,3bR,5aR,7S,9aS,9bS,11aS)-1-(Furan-3-yl)-9a,11a-dimethylhexadecahydro-3aH-cyclopenta[a]phenanthrene-1,3a,7-triol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
PubChem CID
UNII
  • InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1
    Key: AEAPORIZZWBIEX-DTBDINHYSA-N
  • C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@]4(C5=COC=C5)O)O)C)O
Properties
C23H34O4
Molar mass 374.521 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Rostafuroxin is a digitoxigenin analog that has been shown to lower blood pressure in an animal model of hypertension. [1] It modulates the effects of the enzyme Na+/K+-ATPase, [1] which maintains sodium and potassium ion gradients across plasma membranes. Rostafuroxin is being studied in clinical trials for the treatment of essential hypertension. [2] [3]

References

  1. 1 2 Ferrari, Patrizia; Ferrandi, Mara; Valentini, Giovanni; Bianchi, Giuseppe (2006). "Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (3): R529 –R535. doi:10.1152/ajpregu.00518.2005. PMID   16467500.
  2. ↑ Ferrari, Patrizia (2010). "Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1802 (12): 1254–1258. doi: 10.1016/j.BBAdis.2010.01.009 . PMID   20083196.
  3. ↑ Valentini, Giovanni (16 June 2011). "Efficacy of Rostafuroxin in the Treatment of Essential Hypertension". clinicaltrials.gov.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.